SCHEMBL18249869

SCHEMBL18249869

CNS(=O)(=O)Cc1ccc(Oc2cc(C=O)ccn2)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 5/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LOXL2 Q9Y4K0 6/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 2/20 0.35
HPGD P15428 2/20 0.35
MAPT P10636 1/20 0.35
LOX P28300 4/20 0.35
RAB9A P51151 2/20 0.34
NPC1 O15118 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ACACB O00763 1/20 0.34
MET P08581 2/20 0.34
PGR P06401 1/20 0.34
FFAR1 O14842 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239299 0.81 LOXL2 (0.57) LOXL2LOX
SCHEMBL18249748 0.81 P2RX3 (0.47) LOXL2SMN1; SMN2LMNAACACBFFAR1
SCHEMBL20239198 0.74 DGAT2 (0.37) ALDH1A1LOXL2SMN1; SMN2LMNAHPGD
SCHEMBL20239324 0.74 VNN1 (0.41) LOXL2LOX
SCHEMBL18249856 0.74 LOXL2 (0.39) LOXL2LOXACACBMETFFAR1
SCHEMBL2892270 0.72 LOXL2 (0.53) KDM4EALDH1A1L3MBTL1LOXL2SMN1; SMN2
SCHEMBL20239285 0.72 VNN1 (0.38) ALDH1A1LOXL2LMNAMET
SCHEMBL20239161 0.72 DGAT2 (0.36) LOXL2LOXACACBMET
SCHEMBL20239160 0.72 PGR (0.37) KDM4EALDH1A1LOXL2SMN1; SMN2LMNA
SCHEMBL18249754 0.72 KDR (0.41) KDM4EALDH1A1SMN1; SMN2LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
EP-3298001-A1 NOVEL DGAT2 INHIBITORS Eli Lilly and Company (US) 2018-03-28 EP disclosed
WO-2016187384-A1 NOVEL DGAT2 INHIBITORS ELI LILLY AND COMPANY (US) 2016-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT KDM4E 4070/4885ALDH1A1 1430/4885L3MBTL1 1223/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT KDM4E 3891/4885ALDH1A1 1189/4885L3MBTL1 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.